A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancer

被引：1

作者：

Sibille, Anne ^{[1
]}

Bustin, Frederique ^{[2
]}

Carestia, Luciano ^{[3
]}

Catala, Gaetan ^{[4
]}

Compere, Christophe ^{[5
]}

Cuppens, Kristof ^{[6
]}

Colinet, Benoit ^{[7
]}

Coulon, Stephanie ^{[8
]}

De Brucker, Nele ^{[9
]}

Decoster, Lore ^{[10
]}

Decoster, Lynn ^{[11
]}

Demedts, Ingel ^{[12
]}

Derijcke, Sofie ^{[13
]}

Deschepper, Koen ^{[14
]}

Galdermans, Danny ^{[15
]}

Janssens, Annelies ^{[16
]}

Ocak, Sebahat ^{[17
,18
]}

Oyen, Christel ^{[19
]}

Pat, Karin ^{[6
]}

Pieters, Thierry ^{[20
]}

Pruniau, Vincent ^{[8
]}

Surmont, Veerle ^{[21
]}

Vandekeere, Saar ^{[8
]}

Vansteenkiste, Johan ^{[19
,22
]}

机构：

[1] Univ Hosp Liege, Dept Pulmonol, Liege, Belgium

[2] CHR Citadelle, Dept Pulmonol, Liege, Belgium

[3] Clin Saint Pierre Ottignies, Dept Pulmonol, Ottignies, Belgium

[4] CH Jolimont, Dept Oncol, Haine St Paul, La Louviere, Belgium

[5] CHIREC Hosp, CHIREC Canc Inst, Dept Pulmonol, Brussels, Belgium

[6] Jessa Hosp, Dept Pulmonol & Thorac Oncol, Hasselt, Belgium

[7] Grand Hop Charleroi, Dept Pulmonol, Gilly, Belgium

[8] MSD Belgium, Med Affairs Dept, Brussels, Belgium

[9] Imelda Hosp, Dept Pneumonol, Bonheiden, Belgium

[10] Vrije Univ Brussel VUB, Univ Ziekenhuis Brussel UZ Brussel, Dept Med Oncol, Oncologisch Cent, Brussels, Belgium

[11] AZ Turnhout, Dept Pulmonol, Turnhout, Belgium

[12] AZ Delta, Dept Pulm Dis, Roeselare, Belgium

[13] AZ Groeninge, Dept Pulmonol, Kortrijk, Belgium

[14] Algemeen Ziekenhuis Nikolaas, St Niklaas, Belgium

[15] ZNA Middelheim, Dept Pulmonol, Antwerp, Belgium

[16] Antwerp Univ Hosp, MOCA Thorac Oncol, Edegem, Belgium

[17] CHU UCL Namur, Div Pulmonol, Godinne Site, Yvoir, Belgium

[18] Univ Catholique Louvain UCLouvain, Inst Rech Expt & Clin IREC, Pole Pneumol ENT & Dermatol PNEU, Brussels, Belgium

[19] Univ Hosp KU Leuven, Resp Oncol Unit, Leuven, Belgium

[20] Clin Univ St Luc, Dept Pulmonol, Saint Luc, Belgium

[21] Univ Ghent, Dept Resp Med, Ghent, Belgium

[22] Univ Hosp KU Leuven, Resp Oncol Unit, CONTACT Johan Vansteenkiste, Herestr 49, B-3000 Leuven, Belgium

来源：

ACTA ONCOLOGICA | 2022年 / 61卷 / 06期

关键词：

D O I：

10.1080/0284186X.2022.2063700

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：773 / 776

页数：4

共 50 条

[41] Immunochemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancers
Huang, Shujie
Gao, Zhen
Qiao, Guibin
JAMA ONCOLOGY, 2021, 7 (10) : 1580 - 1580
[42] Docetaxel and gemcitabine combination as first-line treatment in advanced or metastatic non-small-cell lung cancer: A multicenter phase II study
Costa, A
Almodovar, T
Seada, J
Barata, F
Teixeira, E
Queiroga, H
Pires, S
PROCEEDINGS OF THE 9TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE, 2004, : 117 - 120
[43] Psoriasis induced by first-line pembrolizumab in metastatic non-small cell lung cancer: A case report
Gatti, Federica
Caruso, Gianluca
Potenza, Concetta
Santini, Daniele
Petrozza, Vincenzo
Annetta, Alessandro
Ceddia, Serena
Cosimati, Antonella
Brandi, Martina
Sorrentino, Veronica
Proietti, Ilaria
Rossi, Luigi
ONCOLOGY LETTERS, 2023, 26 (01)
[44] Management and potential factors of immunotoxicity in patients with metastatic non-small cell lung cancer receiving first-line treatment with immune checkpoint inhibitors
Pena-Lopez, J.
Jimenez Bou, D.
Gutierrez Sainz, L.
Ruiz-Gutierrez, I.
Alonso-Eiras, J. I.
Navas-Jimenez, C.
Garcia-Zamarriego, A.
Bescos-Royo, M.
Gonzalez-Garcia, M. L.
Martin-Morales, L.
Rueda Lara, A.
Alameda, M.
Martin-Montalvo Perez, G.
Villamayor Sanchez, J.
Cruz Castellanos, P.
Higuera Gomez, O.
de Castro Carpeno, J.
ANNALS OF ONCOLOGY, 2024, 35 : S1091 - S1091
[45] Impact of Precision Medicine Methods on First-Line Therapies in Metastatic Non-Small Cell Lung Cancer
Vakkalagadda, C.
Dressler, D.
Sun, Z.
Silberman, P.
Kocherginsky, M.
Boumber, Y.
Chae, Y. K.
Mohindra, N. A.
Ragam, A.
Patel, J.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S248 - S248
[46] Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer
Peravali, Monica
Ahn, Jaeil
Chen, Kevin
Rao, Suman
Veytsman, Irina
Liu, Stephen V.
Kim, Chul
ONCOLOGIST, 2021, 26 (08): : 694 - 700
[47] Randomized multicenter phase II study with docetaxel in combination with either cisplatin or oxaliplatin as first-line treatment in patients with advanced or metastatic non-small cell lung cancer
Atmaca, A.
Al-Batran, S.
Guener, T.
Pauligk, C.
Koepke, A.
Bernhard, H.
Wenzel, T.
Banat, A. G.
Brueck, P.
Caca, K.
Prasnikar, N.
Kullmann, F.
Jaeger, E.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[48] First-line anlotinib-based combination treatment for patients with advanced non-small cell lung cancer: A threearm, prospective study
Han, B.
Chu, T.
Zhang, W.
Han, B.
Zhang, X.
Shi, C.
Zhong, R.
Zhong, H.
Wang, W.
Gu, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S789 - S789
[49] Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?
Dempke, Wolfram C. M.
Fenchel, Klaus
TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (05) : 538 - 542
[50] Economics of first-line treatment with tislelizumab in patients with nonsquamous non-small cell lung cancer
Wang, Lin
Liu, Ting
Lin, Xihan
Zhang, Yu
Shi, Luwen
You, Ruxu
Liu, Jinyu
IMMUNOTHERAPY, 2024, 16 (20-22) : 1217 - 1226

← 1 2 3 4 5 →